	US 11,835,520 B2
	System, method, apparatus and diagnostic test for Plasmodium vivax
Ivo Mueller, Mount Macedon (AU); Takafumi Tsuboi, Ehime Prefecture (JP); Michael White, Melbourne (AU); and Rhea Longley, Brunswick West (AU)
Assigned to The Walter and Eliza Hall Institute of Medical Research, Parkville (AU)
Appl. No. 16/472,269
Filed by The Walter and Eliza Hall Institute of Medical Research, Parkville (AU)
PCT Filed Dec. 21, 2017, PCT No. PCT/IB2017/001776 § 371(c)(1), (2) Date Jun. 21, 2019, PCT Pub. No. WO2018/130871, PCT Pub. Date Jul. 19, 2018.
Claims priority of provisional application 62/438,963, filed on Dec. 23, 2016.
Prior Publication US 2021/0132063 A1, May 6, 2021
Int. Cl. G01N 33/573 (2006.01); G01N 33/569 (2006.01); C07K 14/415 (2006.01); C07K 16/20 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/56905 (2013.01) [C07K 14/415 (2013.01); C07K 16/205 (2013.01); G01N 33/6857 (2013.01); G01N 2333/445 (2013.01)]

25 Claims

1. A diagnostic test for Plasmodium vivax or Plasmodium ovale, to determine a likelihood of a specific timing of infection by P. vivax or P. ovale in a subject by determining a level of antibodies to a plurality of antigens in a blood sample from the subject, wherein the level is measured of antibody to protein selected from at least one of RBP2b (P25) (PVX_094255) (SEQ ID NO:61) or PVX_099980 (L01) (SEQ ID NO:1) and of at least one antibody to a protein selected from the group consisting of PVX_112670 (SEQ ID NO:23), PVX_087885 (SEQ ID NO:45), PVX_096995 (SEQ ID NO:3), PVX_097625 (SEQ ID NO:67) and PVX_000930 (SEQ ID NO:109), wherein the level of antibody is correlated with the time since infection.